

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
13 April 2023 (13.04.2023)



(10) International Publication Number
WO 2023/057930 A1

(51) International Patent Classification:

A61K 39/12 (2006.01) A61K 39/145 (2006.01)
A61K 9/00 (2006.01) A61P 31/16 (2006.01)
A61K 9/19 (2006.01) A61K 39/00 (2006.01)
A61K 9/51 (2006.01)

(21) International Application Number:

PCT/IB2022/059518

(22) International Filing Date:

05 October 2022 (05.10.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/262,336 08 October 2021 (08.10.2021) US
63/293,652 23 December 2021 (23.12.2021) US
63/408,465 20 September 2022 (20.09.2022) US

(71) Applicant: **PFIZER INC.** [US/US]; 235 East 42nd Street,
New York, New York 10017 (US).

(72) Inventors: **BADKAR, Advait Vijay**; c/o Pfizer Inc., 1
Burtt Road, Andover, Massachusetts 01810 (US). **BHAT-
NAGAR, Bakul Subodh**; c/o Pfizer Inc., 1 Burtt Road, An-
dover, Massachusetts 01810 (US). **DARVARI, Ramin**; c/
o Pfizer Inc., 1 Burtt Road, Andover, Massachusetts 01810
(US). **GARCIA, Miguel Angel**; c/o Pfizer Inc., 401 N. Mid-
dletown Road, Pearl River, New York 10965 (US). **GUO,
Pengbo**; c/o Pfizer Inc., 401 N. Middletown Road, Pearl
River, New York 10965 (US). **LI, Shilong**; c/o Pfizer Inc.,
401 N. Middletown, Pearl River, New York 10965 (US).
SHI, Shuai; c/o Pfizer Inc., 401 N. Middletown Road, Pearl
River, New York 10965 (US). **TCHESALOV, Serguei**; c/
o Pfizer Inc., 1 Burtt Road, Andover, Massachusetts 01810
(US).

(74) Agent: **ZIELINSKI, Bryan C.**; PFIZER INC., 100 Route
206 North, Mail Stop: SOM-PPK4-LLA-403, Peapack,
New Jersey 07977 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE

(54) Title: IMMUNOGENIC LNP COMPOSITIONS AND METHODS THEREOF

(57) Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of ribonucleic acid immunogenic compositions and/or vaccines comprising polynucleotide molecules preferably encoding one or more influenza antigens, such as hemagglutinin antigens, wherein the composition is frozen or lyophilized.

WO 2023/057930 A1